Metastatic pheochromocytoma: Does the size and age matter?
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F11%3A10107124" target="_blank" >RIV/00216208:11310/11:10107124 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/11:8741 RIV/00064165:_____/11:8741
Výsledek na webu
<a href="http://dx.doi.org/10.1111/j.1365-2362.2011.02518.x" target="_blank" >http://dx.doi.org/10.1111/j.1365-2362.2011.02518.x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/j.1365-2362.2011.02518.x" target="_blank" >10.1111/j.1365-2362.2011.02518.x</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Metastatic pheochromocytoma: Does the size and age matter?
Popis výsledku v původním jazyce
Pheochromocytomas are tumours arising from chromaffin tissue located in the adrenal medulla associated with typical symptoms and signs which may occasionally develop metastases, which are defined as the presence of tumour cells at sites where these cellsare not found. This retrospective analysis was focused on clinical, genetic and histopathologic characteristics of primary metastatic versus primary benign pheochromocytomas. We identified 41 subjects with metastatic pheochromocytoma and 108 subjects with apparently benign pheochromocytoma. We assessed dimension and biochemical profile of the primary tumour, age at presentation and time to develop metastases. Subjects with metastatic pheochromocytoma presented at a significantly younger age (41.4 +- 14.7 vs. 50.2 +- 13.7 years;P { 0.001) with larger primary tumours (8.38 +- 3.27 vs. 6.18 +- 2.75 cm; P { 0.001) and secreted more frequently norepinephrine (95.1% vs. 83.3%; P = 0.046) compared to subjects with apparently benign pheochromo
Název v anglickém jazyce
Metastatic pheochromocytoma: Does the size and age matter?
Popis výsledku anglicky
Pheochromocytomas are tumours arising from chromaffin tissue located in the adrenal medulla associated with typical symptoms and signs which may occasionally develop metastases, which are defined as the presence of tumour cells at sites where these cellsare not found. This retrospective analysis was focused on clinical, genetic and histopathologic characteristics of primary metastatic versus primary benign pheochromocytomas. We identified 41 subjects with metastatic pheochromocytoma and 108 subjects with apparently benign pheochromocytoma. We assessed dimension and biochemical profile of the primary tumour, age at presentation and time to develop metastases. Subjects with metastatic pheochromocytoma presented at a significantly younger age (41.4 +- 14.7 vs. 50.2 +- 13.7 years;P { 0.001) with larger primary tumours (8.38 +- 3.27 vs. 6.18 +- 2.75 cm; P { 0.001) and secreted more frequently norepinephrine (95.1% vs. 83.3%; P = 0.046) compared to subjects with apparently benign pheochromo
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
European Journal of Clinical Investigation
ISSN
0014-2972
e-ISSN
—
Svazek periodika
41
Číslo periodika v rámci svazku
10
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
8
Strana od-do
1121-1128
Kód UT WoS článku
000294912200011
EID výsledku v databázi Scopus
—